SCHEMBL9944103

SCHEMBL9944103

Cc1c(Cl)cc(C(=O)Nc2ccc(C(=O)O)cc2)cc1OC(C)C

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.50
ALDH1A1 P00352 1/20 0.50
MAPK1 P28482 1/20 0.50
PKM P14618 2/20 0.49
RORC P51449 1/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
LMNA P02545 1/20 0.47
POLB P06746 1/20 0.47
GAA P10253 1/20 0.47
MCL1 Q07820 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
TAS1R3 Q7RTX0 1/20 0.47
TAS1R1 Q7RTX1 1/20 0.47
TAS1R2 Q8TE23 1/20 0.47
KCNQ3 O43525 1/20 0.46
KCNQ2 O43526 1/20 0.46
CA12 O43570 1/20 0.46
CA2 P00918 1/20 0.46
CA9 Q16790 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9944092 0.91 ALDH1A1 (0.55) MAPTALDH1A1MAPK1PKMMEN1
SCHEMBL1458068 0.89 TAS1R3 (0.52) MAPTALDH1A1MAPK1PKMRORC
SCHEMBL1459229 0.88 PKM (0.52) MAPTALDH1A1MAPK1PKMRORC
SCHEMBL9944102 0.88 NPC1 (0.48) MAPTALDH1A1MAPK1PKMRORC
SCHEMBL9944112 0.88 MEN1 (0.49) MAPTALDH1A1MAPK1PKMMEN1
SCHEMBL1458322 0.86 TAS1R3 (0.60) MAPTALDH1A1MAPK1PKMMEN1
SCHEMBL9944134 0.86 MEN1 (0.58) MAPTALDH1A1MAPK1PKMMEN1
SCHEMBL9944123 0.86 ALDH1A1 (0.49) MAPTALDH1A1MAPK1PKMRORC
SCHEMBL1458247 0.85 TAS1R3 (0.57) MAPTALDH1A1PKMMEN1KMT2A
SCHEMBL9944104 0.84 PKM (0.54) MAPTALDH1A1MAPK1PKMRORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9447028-B2 Therapeutic aryl-amido-aryl compounds and their use KING'S COLLEGE LONDON (GB) 2016-09-20 US disclosed
US-20160039747-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2016-02-11 US disclosed
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use RARA, RARB, RARG MAPT 150/4885ALDH1A1 128/4885MAPK1 1666/4885
US-20160039747-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use RARA, RARB, RARG MAPT 150/4885ALDH1A1 128/4885MAPK1 1666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.